IL304375A - Biomarkers for cancer treatment using mdm2 antagonists - Google Patents
Biomarkers for cancer treatment using mdm2 antagonistsInfo
- Publication number
- IL304375A IL304375A IL304375A IL30437523A IL304375A IL 304375 A IL304375 A IL 304375A IL 304375 A IL304375 A IL 304375A IL 30437523 A IL30437523 A IL 30437523A IL 304375 A IL304375 A IL 304375A
- Authority
- IL
- Israel
- Prior art keywords
- biomarkers
- cancer therapy
- mdm2 antagonists
- mdm2
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91045—Acyltransferases (2.3)
- G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
- G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2103080.4A GB202103080D0 (en) | 2021-03-04 | 2021-03-04 | Cancer biomarkers |
| PCT/IB2022/051906 WO2022185260A1 (en) | 2021-03-04 | 2022-03-04 | Biomarkers for cancer therapy using mdm2 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304375A true IL304375A (en) | 2023-09-01 |
Family
ID=75339986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304375A IL304375A (en) | 2021-03-04 | 2023-07-10 | Biomarkers for cancer treatment using mdm2 antagonists |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240293364A1 (https=) |
| EP (1) | EP4301875A1 (https=) |
| JP (1) | JP2024508895A (https=) |
| KR (1) | KR20230150285A (https=) |
| CN (1) | CN117295825A (https=) |
| AU (1) | AU2022230312A1 (https=) |
| BR (1) | BR112023017572A2 (https=) |
| CA (1) | CA3205532A1 (https=) |
| GB (1) | GB202103080D0 (https=) |
| IL (1) | IL304375A (https=) |
| MX (1) | MX2023010258A (https=) |
| TW (1) | TW202302087A (https=) |
| WO (1) | WO2022185260A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2023134707A1 (en) * | 2022-01-11 | 2023-07-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for treating aml-mrc and mds |
| WO2024243078A1 (en) * | 2023-05-19 | 2024-11-28 | Leapfrog Bio, Inc. | Hsp90 inhibitors for the treatment of cancer |
| TW202540077A (zh) * | 2023-11-16 | 2025-10-16 | 日商大塚製藥股份有限公司 | 具有抗癌活性之mdm2-p53交互作用的異吲哚啉酮抑制劑的中間體的製造方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| UA107814C2 (uk) | 2009-11-12 | 2015-02-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи мdм2 |
| WO2011058367A2 (en) * | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| EP2958893B1 (en) | 2013-02-21 | 2017-05-03 | F. Hoffmann-La Roche AG | Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| BR112015029976A2 (pt) | 2013-06-24 | 2017-07-25 | Hoffmann La Roche | formulação farmacêutica, formulação liofilizada farmacêutica e preparações novas, métodos e usos |
| KR20220136454A (ko) | 2013-09-04 | 2022-10-07 | 다이이찌 산쿄 가부시키가이샤 | 스피로옥시인돌 유도체의 제조 방법 |
| US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| CA2945527C (en) | 2014-04-17 | 2022-05-17 | The Regents Of The University Of Michigan | Mdm2 inhibitors and therapeutic methods using the same |
| JP2017532959A (ja) * | 2014-10-09 | 2017-11-09 | 第一三共株式会社 | Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| WO2017205786A1 (en) | 2016-05-27 | 2017-11-30 | Aileron Therapeutics, Inc. | Cell permeable peptidomimetic macrocycles |
| GB201704965D0 (en) * | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CA3050645A1 (en) * | 2018-07-27 | 2020-01-27 | Ottawa Hospital Research Institute | Treatment of acute myeloid leukemia |
| EP3814525A4 (en) * | 2019-02-24 | 2022-04-13 | Ascentage Pharma (Suzhou) Co., Ltd. | TREATMENT METHODS AND BIOMARKERS FOR MDM2 INHIBITORS |
| GB201919219D0 (en) * | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2021
- 2021-03-04 GB GBGB2103080.4A patent/GB202103080D0/en not_active Ceased
-
2022
- 2022-03-04 US US18/548,522 patent/US20240293364A1/en active Pending
- 2022-03-04 BR BR112023017572A patent/BR112023017572A2/pt unknown
- 2022-03-04 KR KR1020237028389A patent/KR20230150285A/ko active Pending
- 2022-03-04 WO PCT/IB2022/051906 patent/WO2022185260A1/en not_active Ceased
- 2022-03-04 MX MX2023010258A patent/MX2023010258A/es unknown
- 2022-03-04 CN CN202280017371.3A patent/CN117295825A/zh active Pending
- 2022-03-04 AU AU2022230312A patent/AU2022230312A1/en active Pending
- 2022-03-04 CA CA3205532A patent/CA3205532A1/en active Pending
- 2022-03-04 JP JP2023553324A patent/JP2024508895A/ja active Pending
- 2022-03-04 EP EP22707524.9A patent/EP4301875A1/en active Pending
- 2022-03-04 TW TW111108020A patent/TW202302087A/zh unknown
-
2023
- 2023-07-10 IL IL304375A patent/IL304375A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022185260A1 (en) | 2022-09-09 |
| JP2024508895A (ja) | 2024-02-28 |
| MX2023010258A (es) | 2023-09-12 |
| CA3205532A1 (en) | 2022-09-09 |
| KR20230150285A (ko) | 2023-10-30 |
| AU2022230312A9 (en) | 2025-03-13 |
| AU2022230312A1 (en) | 2023-07-13 |
| GB202103080D0 (en) | 2021-04-21 |
| CN117295825A (zh) | 2023-12-26 |
| EP4301875A1 (en) | 2024-01-10 |
| TW202302087A (zh) | 2023-01-16 |
| BR112023017572A2 (pt) | 2023-10-10 |
| US20240293364A1 (en) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304375A (en) | Biomarkers for cancer treatment using mdm2 antagonists | |
| IL276528A (en) | Halogen-labeled urea-polyaminocarboxylates targeting PSMA for cancer radiotherapy | |
| SG11202101397TA (en) | Biomarkers for cancer therapy | |
| GB201919219D0 (en) | Cancer biomarkers | |
| IL291621A (en) | A complex biomarker for cancer treatment | |
| IL282093A (en) | Combination therapy for cancer | |
| EP4291902A4 (en) | BIOMARKERS FOR CANCER TREATMENT | |
| GB202007099D0 (en) | Tumour biomarkers for immunotherapy | |
| GB202108237D0 (en) | Cancer methods | |
| IL304436A (en) | Cancer treatment | |
| HUE071473T2 (hu) | MIV-818/lenvatinib kombinációs terápia májrák kezelésére | |
| IL304550A (en) | Biomarkers for fimpinostat therapy | |
| HK40100061A (en) | Biomarkers for cancer therapy using mdm2 antagonists | |
| HK40089616A (en) | Biomarkers for cancer therapy using mdm2 antagonists | |
| EP3847282A4 (en) | BIOMARKERS FOR CANCER THERAPY | |
| HK40075685A (en) | Biomarkers for cancer therapy using mdm2 antagonists | |
| GB202218395D0 (en) | Cancer therapy | |
| IL304200A (en) | Combined treatment using anti-fucosyl-gm1 antibody | |
| IL307858A (en) | Colon cancer biomarkers | |
| GB2594103B (en) | Prostate cancer biomarkers | |
| GB202001963D0 (en) | Cancer therapy | |
| SG11202109025XA (en) | Combinations of iadademstat for cancer therapy | |
| GB202014323D0 (en) | Assay for assessing cancer | |
| GB202314087D0 (en) | Biomarker for cancer | |
| GB202116680D0 (en) | Combination therapy for cancer |